Alps Advisors Inc Aadi Bioscience, Inc. Transaction History

Alps Advisors Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$4.84 - $7.13 $624 - $919	129 Added 0.72%	18,094 $87,000
Q2 2023 Aug 14, 2023	BUY	$6.84 - $8.56 $12,934 - $16,186	1,891 Added 11.76%	17,965 $122,000
Q1 2023 May 10, 2023	SELL	$6.85 - $13.0 $3,205 - $6,084	-468 Reduced 2.83%	16,074 $116,000
Q4 2022 Feb 14, 2023	BUY	$11.99 - $14.5 $60,345 - $72,978	5,033 Added 43.73%	16,542 $212,000
Q3 2022 Nov 14, 2022	SELL	$12.03 - $14.22 $10,995 - $12,997	-914 Reduced 7.36%	11,509 $163,000
Q2 2022 Aug 11, 2022	SELL	$11.57 - $17.92 $104,662 - $162,104	-9,046 Reduced 42.14%	12,423 $153,000
Q1 2022 May 16, 2022	SELL	$16.65 - $24.97 $45,038 - $67,543	-2,705 Reduced 11.19%	21,469 $364,000
Q4 2021 Feb 09, 2022	BUY	$19.32 - $29.02 $467,041 - $701,529	24,174 New	24,174 $584,000

12.6M

23.8K

Ticker AADI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,016,800
Market Cap $75.7M
Description
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.